

Product Roadmap Notes:

- Prasanna: The “big whitespace” before clinical conduct which has not been captured
 - Q: “what is saama's plan for building tools in that space, or is Saama looking for partners”
 - A (Nekzad): Study Planning Insights covers feasibility, site selection, patient identification, study diversity, etc.
- Jeremy Cronin (Dicerna) asked about centralized data management for integrating clinical and commercial data (RWE, bio-bank data, master metadata set)
 - Nekzad: Commercial insights coming to the fore (post approval) with use cases: physician targeting, KOL identification, contracting, sales messaging, claims datasets, GPO contracting, doctor site contracting, etc.
 - Jeremy also asked questions about unstructured data source ingestion
- Sam Tomioka - asked nekzad to elaborate on clinical neural networks
 - Dr. DaLIA network
- Prasana: when does diversity in clinical trials come in?
 - Nekzad: built into study planning insights, part of a Q1 2021 launch

Clinical Analytics Notes Breakout Room Notes

- Jeremy Cronin: Saama is based in a lot of domains that are not directly applicable to dicerna - need to work off raw data a bit better
 - KPI studio needs to be more performant, documentation needs to be a lot cleaner - I (sean) can reach out to Jeremy about this
 - Jeremy can't get his dashboards look a certain way, but would like to be able to
- Chris Colucci - wants to see a bit more information on meeting dates (he would like LSAC 3.X or 4.0 to be announced several weeks in advance); they need a bit more time to prepare and go through UAT
- Other general concerns:
 - Improved training content needed for KPI studio
 - Oversight Scorecard too EDC centric

- Oversight Scorecard Notes (from Haritha's presentation)
 - Good portion of our audience had seen oversight scorecard
 - AE rate thresholds can be matured, as can other focus areas
 - Some thresholds don't work for a certain TA, for example
 - Need to incorporate other metric categories: targeted SDV
 - are we under-monitoring, over monitoring?
 - Haritha: adding self-service capabilities in the next-year is a focus for oversight scorecard
 - Notion of benchmarking within Oversight scorecard
 - Where are industry benchmarks coming from?
- Portfolio Summary at a TA level is extremely important (how is a site performing across all studies)
- Notifications: how to toe the line between notifications on study specifics for different users
 - Change management concerns here: need to understand how this would take place.
 - In-app notifications vs email
- New Dashboard Summary:
 - Portfolio summary analytics (TA level)
 - Benchmarking information for indications, TA's, etc?
- Anirban did not have much time to present upcoming dashboards/analytics for feedback, he will reach out personally to some attendees for feedback